These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31651221)

  • 1. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
    Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
    Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
    Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
    Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.
    Rice LB; Carias LL; Hujer AM; Bonafede M; Hutton R; Hoyen C; Bonomo RA
    Antimicrob Agents Chemother; 2000 Feb; 44(2):362-7. PubMed ID: 10639363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
    Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
    Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.
    French GL; Shannon KP; Simmons N
    J Clin Microbiol; 1996 Feb; 34(2):358-63. PubMed ID: 8789016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF; Zhou J; Qin JP
    Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
    Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
    Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Stainton SM; Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
    Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    Rice LB; Carias LL; Bonomo RA; Shlaes DM
    J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
    Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
    Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
    Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.
    Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK
    Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.